Aim immunotech announces report of complete topline data from roswell park comprehensive cancer center study evaluating ampligen® as a component of a chemokine-modulating (ckm) regimen, with paclitaxel, for the treatment of early-stage triple negative breast cancer

Complete topline results confirm treatment was well tolerated, with promising clinical activity of pathologic complete response (pcr) + microinvasive residual disease (yptmic) at 66%, comparable to pembrolizumab/neoadjuvant chemotherapy (nac)
AIM Ratings Summary
AIM Quant Ranking